Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
Gatell
Jose M
JM
University of Barcelona, Barcelona, Spain.
Katlama
Christine
C
Grinsztejn
Beatriz
B
Eron
Joseph J
JJ
Lazzarin
Adriano
A
Vittecoq
Daniel
D
Gonzalez
Charles J
CJ
Danovich
Robert M
RM
Wan
Hong
H
Zhao
Jing
J
Meibohm
Anne R
AR
Strohmaier
Kim M
KM
Harvey
Charlotte M
CM
Isaacs
Robin D
RD
Nguyen
Bach-Yen T
BY
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D018791:CD4 Lymphocyte Count; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium